Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Non-Alcoholic Fatty Liver Disease
Investigation on Safety and Efficacy of Soybean Fermented Extract (MBS217) in Treating Patients With NAFLD
Investigators aimed to investigate the efficacy and safety of fermented soybean extract (MBS-217) in treating participants with Non-alcoholic fatty liver disease (NAFLD) in this study.
- Trial name
- NCT05686174
- Testing
- MBS217
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
Aim: 1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department. 2.
- Trial name
- NCT00375349
- Testing
- Ultrasound to demonstrate existence of fatty liver
- Sponsor
- Shaare Zedek Medical Center
Non-Alcoholic Fatty Liver Disease
To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation
In this study, the improvement of the clinical status of early-stage non-alcoholic fatty liver disease (NAFLD) patients after the probiotic intervention will be assessed.
- Trial name
- NCT05402449
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- GenMont Biotech Incorporation
HIV, Fatty Liver
Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients
People infected with HIV are living longer thanks to the use of antiretroviral therapy (cART). In aging HIV persons, other factors are associated with early death.
- Conditions
- HIV, Fatty Liver, Nonalcoholic Steatohepatitis
- Trial name
- NCT02210715
- Testing
- Isentress., Continue usual antiretroviral therapy
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Non-alcoholic Fatty Liver Disease, Sleep Apnea, Obstructive
Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease
Obstructive sleep apnea (OSA) and nonalcoholic fatty liver disease (NAFLD) are frequently encountered in patients with metabolic syndrome (MS). Several data suggest that OSA per se could be a risk factor of liver injury.
- Trial name
- NASHSAS (NCT03373643)
- Testing
- OSA screening
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Non-Alcoholic Fatty Liver Disease
Micro RNA Levels in NAFLD
Epidemiological study of NAFLD, NASH patients. Descriptions of altered miRNA profiles in NAFLD patients especially with fibrosis.
- Trial name
- NCT04574557
- Testing
- micro RNA
- Volunteers
- 80 people
- Sponsor
- Assiut University
Healthy
31P Magnetic Resonance Spectroscopy Fructose Study
The purpose of this study is to determine the effects of an oral fructose challenge on liver adenosine triphosphate (ATP) reserves using 31P magnetic resonance spectroscopy (MRS) as a potential measure measure of liver health.
- Trial name
- 31PMRS_FRU (NCT02217605)
- Testing
- Fructose
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stephen Bawden
NAFLD, Fatty Liver
Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome
Concurrent with the rising prevalence of childhood obesity, the co-morbid condition of non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease among children.
- Conditions
- NAFLD, Fatty Liver, Obesity, Metabolic Syndrome
- Trial name
- NAFLD (NCT02358928)
- Testing
- Diet Intervention
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass index and waist…
- Trial name
- NCT01759628
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Tehran University of Medical Sciences
NAFLD
French Cohort for the Study of Non-invasive Tests of Liver Lesions in NAFLD/NASH (FreSH Cohort)
Currently, the management of non-alcoholic fatty liver disease (NAFLD) patients has two main limitations. First, there is no approved treatment in NAFLD.
- Trial name
- FreSH (NCT03695796)
- Testing
- biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank
- Where
- 16 sites in France, Guadeloupe
- Volunteers
- 1,005 people
- Sponsor
- University Hospital, Angers
Lipodystrophy
Leptin to Treat Lipodystrophy
This study will evaluate the safety and effectiveness of the leptin replacement therapy in treating lipoatrophy or lipodystrophy-a condition in which there is a total or partial loss of fat cells.
- Trial name
- NCT00005905
- Testing
- hu Leptin (A-100)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fatty Liver, Dyslipidemias
Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
The purpose of the study is to compare the impact of atorvastatin 20mg qd and Vitamin E 300mg qd therapy on liver fat content in patients with type 2 diabetes associated with high LDL-C and non-alcoholic fatty liver disease.
- Conditions
- Fatty Liver, Dyslipidemias, Diabetes Mellitus
- Trial name
- NCT01720719
- Testing
- atorvastatin, Vitamin E
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xin Gao
Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin
The first line approach to NAFLD is currently based on diet and lifestyle modification. Aim of our Unit is to compare the efficacy of two different doses of metformin (1 g/day and 2 g/day) with atorvastatin (20 mg/day) on…
- Trial name
- NCT01544751
- Testing
- Low dose metformin, Metformin, Atorvastatin
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Prof Antonino Belfiore
Fatty Liver Disease, Fatty Infiltration
Fatty Liver Among Employees at Banha University
This was cross sectional study at Banha University Hospital among employees. Age of the subjects from 20-60 years old both males and females .All investigations done plus abdominal ultrasound for grading of fatty liver and dopler…
- Trial name
- fattyliver (NCT04367012)
- Testing
- Abdominal Ultrasound
- Where
- Egypt
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Benha University
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate the effect of weight loss rate on liver steatosis, steatohepatitis, fibrosis and cardiovascular risk at different stages before and after bariatric surgery.
- Trial name
- NCT01828528
- Testing
- Sleeve gastrectomy
- Where
- Israel
- Volunteers
- 26 people
- Sponsor
- Sheba Medical Center
Non-alcoholic Fatty Liver Disease
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
The primary purpose of this study is to evaluate the effect of hepatic impairment on the systemic exposure of tropifexor and to evaluate the safety of tropifexor in subjects with hepatic impairment.
- Trial name
- NCT03681457
- Testing
- LJN452
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Mediterranean Diet
Mediterranean Diet Treatment for NAFLD
Treatment for Nonalcoholic Fatty Liver Disease (NAFLD) is through lifestyle modification consisting of caloric restriction and exercise, with an emphasis on weight loss.
- Trial name
- NCT04415112
- Testing
- Mediterranean Diet, Low Fat Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Antalya Training and Research Hospital
NAFLD
The Role of Microbiome Reprogramming on Liver Fat Accumulation
The purpose of this study is to investigate whether reprogramming the microbiome via soluble fiber supplementation will decrease liver fat in obese individuals.
- Trial name
- MILE (NCT03914495)
- Testing
- Inulin
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Heart Failure With Preserved Ejection Fraction, Non Alcoholic Fatty Liver
Relationship Between Heart Failure With Preserved Ejection Fraction and Nonalcoholic Fatty Liver Disease.
The aim of our study to determine the demography, relation between patients with heart failure with preserved ejection fraction and those with nonalcoholic fatty liver disease in Sohag university hospital.
- Trial name
- NCT05822622
- Testing
- echocardiography
- Where
- 2 sites in Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University